NEW YORK (GenomeWeb) – KineMed and Camino Partnership today announced that they are partnering in an effort to acquire new drugs and targeted drug candidates for potential licensing opportunites.

According to the partners, KineMed plans to apply its proteomics technology in rapid proof-of-concept studies on up to six compounds over a three-year period and then out-license appropriate candidate drugs to pharmaceutical companies.

Initially, the effort will focus on drugs for oncology, neurodegenerative disorders, muscle wasting, and fibrosis diseases, the companies said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.